Kazuo Kasahara

9.6k total citations
255 papers, 3.7k citations indexed

About

Kazuo Kasahara is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Kazuo Kasahara has authored 255 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Pulmonary and Respiratory Medicine, 112 papers in Oncology and 48 papers in Physiology. Recurrent topics in Kazuo Kasahara's work include Lung Cancer Treatments and Mutations (86 papers), Asthma and respiratory diseases (34 papers) and Colorectal Cancer Treatments and Studies (33 papers). Kazuo Kasahara is often cited by papers focused on Lung Cancer Treatments and Mutations (86 papers), Asthma and respiratory diseases (34 papers) and Colorectal Cancer Treatments and Studies (33 papers). Kazuo Kasahara collaborates with scholars based in Japan, United States and United Kingdom. Kazuo Kasahara's co-authors include Kazuto Nishio, Hideharu Kimura, Masaki Fujimura, Tomohide Tamura, Hideo Kunitoh, Takashi Sone, M Fujimura, Shinji Nakao, Akihiro Yoshimoto and Noriyuki Ohkura and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Kazuo Kasahara

233 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kazuo Kasahara Japan 32 2.5k 1.7k 769 676 546 255 3.7k
Keisuke Aoe Japan 31 2.1k 0.9× 1.5k 0.9× 872 1.1× 587 0.9× 346 0.6× 105 3.4k
Tadashi Mio Japan 33 1.9k 0.8× 1.7k 1.0× 653 0.8× 364 0.5× 481 0.9× 156 3.8k
Brett Hughes Australia 31 2.1k 0.8× 2.3k 1.4× 820 1.1× 696 1.0× 238 0.4× 179 4.4k
Tateaki Naito Japan 37 2.9k 1.2× 2.4k 1.4× 862 1.1× 551 0.8× 1.1k 1.9× 282 5.4k
Koichi Minato Japan 29 1.6k 0.6× 2.1k 1.2× 781 1.0× 364 0.5× 165 0.3× 171 3.1k
Diana N. Ionescu Canada 26 1.1k 0.5× 893 0.5× 625 0.8× 466 0.7× 235 0.4× 78 2.7k
Tatsuro Okamoto Japan 40 2.1k 0.8× 2.3k 1.4× 1.3k 1.6× 633 0.9× 409 0.7× 215 4.9k
Sara Pilotto Italy 29 1.1k 0.4× 1.8k 1.1× 813 1.1× 485 0.7× 197 0.4× 187 2.9k
Aurelius Omlin Switzerland 32 1.9k 0.8× 1.3k 0.8× 816 1.1× 985 1.5× 368 0.7× 115 3.6k
Sun Min Lim South Korea 27 1.6k 0.7× 1.5k 0.9× 900 1.2× 521 0.8× 121 0.2× 132 2.8k

Countries citing papers authored by Kazuo Kasahara

Since Specialization
Citations

This map shows the geographic impact of Kazuo Kasahara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kazuo Kasahara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kazuo Kasahara more than expected).

Fields of papers citing papers by Kazuo Kasahara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kazuo Kasahara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kazuo Kasahara. The network helps show where Kazuo Kasahara may publish in the future.

Co-authorship network of co-authors of Kazuo Kasahara

This figure shows the co-authorship network connecting the top 25 collaborators of Kazuo Kasahara. A scholar is included among the top collaborators of Kazuo Kasahara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kazuo Kasahara. Kazuo Kasahara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kamio, Koichiro, et al.. (2025). Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy. Respiratory Medicine Case Reports. 56. 102237–102237.
4.
Matsumoto, Masaru, Michiko Nakagawa, Yasuhiro Terasaki, et al.. (2024). IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report. Frontiers in Immunology. 15. 1370972–1370972.
5.
6.
Garon, Edward B., Matomo Nishio, Takashi Seto, et al.. (2024). PS1-3 RELAY: final overall survival with erlotinib+ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC). Annals of Oncology. 35. S1313–S1313. 1 indexed citations
7.
Hara, Johsuke, Yoshihiro Takeda, Takafumi Kobayashi, et al.. (2023). Bronchial Thermoplasty Attenuates Cough Reflex Sensitivity in Severe Asthma : A Single-Center Retrospective Study with 2-year Follow-up. The Journal of Medical Investigation. 70(1.2). 271–275. 1 indexed citations
8.
9.
Horinouchi, Hidehito, Naoyuki Nogami, Hideo Saka, et al.. (2021). Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study. Cancer Science. 112(8). 3255–3265. 40 indexed citations
10.
Ishiura, Yoshihisa, Masaki Fujimura, Noriyuki Ohkura, et al.. (2020). <p>Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap</p>. International Journal of COPD. Volume 15. 269–277. 13 indexed citations
11.
Hara, Johsuke, Takafumi Kobayashi, Noriyuki Ohkura, et al.. (2019). The prevalence and clinical features of asthma-COPD overlap (ACO) definitively diagnosed according to the Japanese Respiratory Society Guidelines for the Management of ACO 2018. The Journal of Medical Investigation. 66(1.2). 157–164. 15 indexed citations
12.
Horinouchi, Hidehito, Naoyuki Nogami, Hideo Saka, et al.. (2019). Safety/Tolerability of 1L Pembrolizumab+Chemotherapy in Japanese Patients with Metastatic Nonsquamous NSCLC: KEYNOTE-189. 3–9.
13.
Murakami, Haruyasu, Yuichiro Ohe, Toyoaki Hida, et al.. (2017). Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Annals of Oncology. 28. v483–v483. 1 indexed citations
14.
Kasahara, Kazuo, et al.. (2011). . Journal of the Japan Society for Precision Engineering. 77(10). 966–971. 2 indexed citations
15.
Kasahara, Kazuo, et al.. (2010). Analysis of Tool Deflection and Mechanism of Surface Generation in Ball End Milling of an Inclined Surface (2nd Report). Journal of the Japan Society for Precision Engineering. 76(8). 901–906. 4 indexed citations
16.
Hara, Johsuke, Masaki Fujimura, Shigeharu Myou, et al.. (2008). Effect of Pressure Stress Applied to the Airway on Cough-Reflex Sensitivity in Guinea Pigs. American Journal of Respiratory and Critical Care Medicine. 177(6). 585–592. 30 indexed citations
17.
Ishiguro, Takashi, Kazuo Kasahara, Hideharu Kimura, Masahide Yasui, & Masaki Fujimura. (2007). Diabetes Insipidus Induced by Metastasis of Lung Adenocarcinoma to Pituitary Gland -Case Report-. Haigan. 47(2). 125–130.
18.
Kimura, Hideharu, Hisao Fukumoto, Sarah Park, et al.. (2005). Deletional mutant EGFR detected in circulating tumor-derived DNA from lung cancer patients treated with gefitinib.. Cancer Research. 65. 112–112.
19.
Kurashima, Kazuyoshi, Masaki Fujimura, Shigeharu Myou, et al.. (2001). Effects of Oral Steroids on Blood CXCR3+ and CCR4 + T Cells in Patients with Bronchial Asthma. American Journal of Respiratory and Critical Care Medicine. 164(5). 754–758. 27 indexed citations
20.
Yasui, Masahide, et al.. (1989). [2-color analysis of lymphocyte subpopulation of bronchoalveolar lavage fluid and peripheral blood in patients with sarcoidosis].. PubMed. 27(9). 1066–73. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keisuke Aoe Breakdown of academic impact, for papers by Tadashi Mio Breakdown of academic impact, for papers by Brett Hughes Breakdown of academic impact, for papers by Tateaki Naito Breakdown of academic impact, for papers by Koichi Minato Breakdown of academic impact, for papers by Diana N. Ionescu Breakdown of academic impact, for papers by Tatsuro Okamoto Breakdown of academic impact, for papers by Sara Pilotto Breakdown of academic impact, for papers by Aurelius Omlin Breakdown of academic impact, for papers by Sun Min Lim
Rankless by CCL
2026